Lipids

, Volume 39, Issue 11, pp 1125–1132

Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers

  • Charles N. Serhan
  • Makoto Arita
  • Song Hong
  • Katherine Gotlinger
Article

DOI: 10.1007/s11745-004-1339-7

Cite this article as:
Serhan, C.N., Arita, M., Hong, S. et al. Lipids (2004) 39: 1125. doi:10.1007/s11745-004-1339-7

Abstract

The molecular basis for the beneficial impact of essential omega-3 (n−3) FA remains of interest. Recently, we identified novel mediators generated from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that displayed potent bioactions identified first in resolving inflammatory exudates and in tissues enriched with DHA. The trivial names resolvin (resolution phase interaction products) and docosatrienes were introduced for the bioactive compounds from these novel series since they possess potent anti-inflammatory and immunoregulatory actions. Compounds derived from EPA carrying potent biological actions (i.e., 1–10 nM range) are designated E series and denoted resolvins of the E series (resolvin E1 or RvE1), and those biosynthesized from the precursor DHA are denoted resolvins of the D series (resolvin D1 or RvD1). The number 1 designates the bioactive compounds in this family (e.g., 1–4). Bioactive members from DHA-containing conjugated triene structures or docosatrienes (DT) that possess immunoregulatory and neuroprotective actions were termed neuroprotectins. Aspirin treatment initiates a related epimeric series by triggering endogenous formation of the 17R-D series resolvins and docosatrienes. These epimers are denoted as aspirin-triggered (AT)-RvD and DT, and possess potent anti-in-flammatory actions in vivo essentially equivalent to their 17S series pathway products. These include five distinct series: (i) 18R resolvins from EPA (i.e., RvE1); (ii) 17R series (AT) resolvins from DHA (RvD1 through RvD4); (iii) 17S series resolvins from DHA (RvD1 through RvD4), (iv) DT from DHA; and (v) their AT form 17R series DT. In this article, we provide an overview of the formation and actions of these newly uncovered pathways and products.

Abbreviations

17R-HDHA

17R-hydroxy-docosahexaenoic acid

18R-HEPE

18R-hydroxy-5Z,8Z,11Z,14Z,16E-eicosapentaenoic acid

ASA

aspirin

AT

aspirin-triggered

ATL

aspirin-triggered lipoxin

COX

cyclooxygenase

DHA

docosahexaenoic acid

DT

docosatrienes

EPA

eicosapentaenoic acid

IL

interleukin

LOX

lipoxygenase

LX

lipoxins

PMN

polymorphonuclear neutrophils

RvD1

resolvin D1

RvE1

resolvin E1

TNF

tumor necrosis factor α

Copyright information

© AOCS Press 2004

Authors and Affiliations

  • Charles N. Serhan
    • 1
  • Makoto Arita
    • 1
  • Song Hong
    • 1
  • Katherine Gotlinger
    • 1
  1. 1.Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain MedicineBrigham and Women's Hospital and Harvard Medical SchoolBoston